iBio, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 08/10/2026 BST			5-day change	1st Jan Change
0.9200 ^USD	-8.91%		-22.03%	-52.33%

09-17	HC Wainwright Initiates iBio With Buy Rating, $7 Price Target	MT
08-28	IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI

Published on 03/17/2026 at 09:20 pm GMT - Modified on 03/18/2026 at 05:20 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the iBio conference call. [Operator Instructions] Please be advised that today's conference is

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-17	HC Wainwright Initiates iBio With Buy Rating, $7 Price Target	MT
08-28	IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-04	Ibio, Inc. Announces Appointment of Molly Carr as Chief Medical Officer	CI
07-01	IBio Reports Single Dose of IBIO-610 Achieves Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study	CI
06-29	IBio, Inc.(NasdaqCM:IBIO) added to Russell Microcap Value Benchmark Index	CI
06-29	IBio, Inc.(NasdaqCM:IBIO) added to Russell 3000E Index	CI
06-28	IBio, Inc.(NasdaqCM:IBIO) added to Russell 3000E Value Benchmark	CI
06-28	IBio, Inc.(NasdaqCM:IBIO) added to Russell Microcap Index	CI
06-08	Raymond James Initiates iBio at Outperform With $5 Price Target	MT
06-05	B. Riley Initiates iBio at Buy With $6 Price Target	MT
06-02	Ibio Doses First Participant in Phase 1 Clinical Trial of Ibio-600 in Adults with Obesity	CI
05-12	IBio reports Q3 fiscal year 2026 financial results and provides corporate update	RE
05-12	IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-08	IBio, Inc. Announces Board and Committee Changes, Effective May 7, 2026	CI
04-08	IBio, Inc. Receives Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of Ibio-600 in Australia	CI

Duration

Period

Sector